Less than a year after it was spun out of Spanish biotech firm Zeltia, Sylentis is hoping to become a major player in the RNAi drugs field with programs in ophthalmology and digestive disease.
The company, which currently has five full-time employees focused on research and development, is also in the process of establishing a scientific advisory board to help shepherd its lead drug compound — a treatment for glaucoma — through primate testing and into the clinic.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.